mTOR: A Potential Therapeutic Target in Osteoarthritis?

Drugs in R and D

Volumn 15, Issue 1, 2015, Pages 27-36

  Pal, Bandna ^a   Endisha, Helal ^a   Zhang, Yue ^a   Kapoor, Mohit ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TEMSIROLIMUS; TARGET OF RAPAMYCIN KINASE;

ARTICULAR CARTILAGE; CELL AGING; CHONDROGENESIS; DRUG TARGETING; GROWTH, DEVELOPMENT AND AGING; HOMEOSTASIS; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; OSTEOARTHRITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; GENE DELETION; GENETICS; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ANIMALS; DISEASE MODELS, ANIMAL; GENE DELETION; HUMANS; MICE; MOLECULAR TARGETED THERAPY; OSTEOARTHRITIS; SEVERITY OF ILLNESS INDEX; TOR SERINE-THREONINE KINASES;

EID: 84925535109     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-015-0082-z     Document Type: Review

References (109)

1. Loeser RF. Aging and osteoarthritis: the role of chondrocyte senescence and aging changes in the cartilage matrix. Osteoarthritis Cartilage. 2009;17(8):971–9.
2. Grogan SP, D’Lima DD. Joint aging and chondrocyte cell death. Int J Clin Rheumtol. 2010;5(2):199–214.
3. Lotz MK, Carames B. Autophagy and cartilage homeostasis mechanisms in joint health, aging and OA. Nat Rev Rheumatol. 2011;7(10):579–87.
4. Carames B, et al. Autophagy is a protective mechanism in normal cartilage, and its aging-related loss is linked with cell death and osteoarthritis. Arthritis Rheum. 2010;62(3):791–801.
5. Lotz M, Loeser RF. Effects of aging on articular cartilage homeostasis. Bone. 2012;51(2):241–8.
6. Li Y, Wei X, Zhou J, et al. The age-related changes in cartilage and osteoarthritis. Biomed Res Int. 2013;2013:916530.
7. García-Carvajal ZY, Garciadiego-Cazares D, Parra-Cid C, et al. Cartilage tissue engineering: the role of extracellular matrix (ECM) and novel strategies. In: Andrades JA, editor. Regenerative medicine and tissue engineering. Croatia: InTech; 2013. pp. 365–97.
8. Almonte-Becerril M, Navarro-Garcia F, Gonzalez-Robles A, et al. Cell death of chondrocytes is a combination between apoptosis and autophagy during the pathogenesis of Osteoarthritis within an experimental model. Apoptosis. 2010;15(5):631–8.
9. Lotz MK, Otsuki S, Grogan SP, et al. Cartilage cell clusters. Arthritis Rheum. 2010;62(8):2206–18.
10. Sandell LJ, Aigner T. Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res. 2001;3(2):107–13.
11. Cecconi F, Levine B. The role of autophagy in mammalian development: cell makeover rather than cell death. Dev Cell. 2008;15(3):344–57.
12. Mizushima, N. Physiological Functions of Autophagy. In: Levine B, Yoshimori T, Deretic V, editors. Autophagy in infection and immunity. Berlin: Springer; 2009. pp. 71–84.
13. Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy. 2011;7(3):279–96.
14. Chan EY, Tooze SA. Evolution of Atg1 function and regulation. Autophagy. 2009;5(6):758–65.
15. Chan EY, Kir S, Tooze SA. siRNA screening of the kinome identifies ULK1 as a multidomain modulator of autophagy. J Biol Chem. 2007;282(35):25464–74.
16. Furuya N, Yu J, Byfield M, Pattingre S, Levine B. The evolutionarily conserved domain of Beclin 1 is required for Vps34 binding, AUTOPHAGY, and tumor suppressor function. Autophagy. 2005;1(1):46–52.
17. Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19(21):5720–8.
18. Martin JA, Buckwalter JA. The role of chondrocyte senescence in the pathogenesis of osteoarthritis and in limiting cartilage repair. J Bone Joint Surg Am. 2003; 85-A (Suppl 2):106–10.
19. Hayflick L. Intracellular determinants of cell aging. Mech Ageing Dev. 1984;28(2–3):177–85.
20. Martin JA, Buckwalter JA. Telomere erosion and senescence in human articular cartilage chondrocytes. J Gerontol A Biol Sci Med Sci. 2001;56(4):B172–9.
21. Campisi J, d’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8(9):729–40.
22. Buckwalter JA, Mankin HJ. Articular cartilage: degeneration and osteoarthritis, repair, regeneration, and transplantation. Instr Course Lect. 1998;47:487–504.
23. Toussaint O, Medrano EE, von Zglinicki T. Cellular and molecular mechanisms of stress-induced premature senescence (SIPS) of human diploid fibroblasts and melanocytes. Exp Gerontol. 2000;35(8):927–45.
24. Golden TR, Melov S. Mitochondrial DNA mutations, oxidative stress, and aging. Mech Ageing Dev. 2001;122(14):1577–89.
25. Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle. 2008;7(21):3355–61.
26. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011;192(4):547–56.
27. Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975;28(10):721–6.
28. Siekierka JJ, Wiederrecht G, Greulich H, Boulton D, Hung SH, Cryan J, Hodges PJ, Sigal NH. The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. J Biol Chem. 1990;265(34):21011–5.
29. Wiederrecht G, Hung S, Chan HK, et al. Characterization of high molecular weight FK-506 binding activities reveals a novel FK-506-binding protein as well as a protein complex. J Biol Chem. 1992;267(30):21753–60.
30. Heitman J, Movva NR, Hiestand PC, Hall MN. FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in saccharomyces cerevisiae. Proc Natl Acad Sci. 1991;88:1948–52.
31. Lorenz MC, Heitman J. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J Biol Chem. 1995;270(46):27531–7.
32. Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast TOR, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci. 1994;91:12574–8.
33. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem. 1995;270(2):815–22.
34. Helliwell SB, Wagner P, Kunz J, et al. TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. Mol Biol Cell. 1994;5(1):105–18.
35. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN. Two TOR complexes, only one of which is rapamycin sensitive, Have distinct roles in cell growth control. Mol Cell. 2002;10:457–68.
36. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14(14):1296–302.
37. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926–45.
38. Dobashi Y, Watanabe Y, Miwa C, et al. Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol. 2011;4(5):476–95.
39. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–84.
40. Cutler NS, Pan X, Heitman J, et al. The TOR signal transduction cascade controls cellular differentiation in response to nutrients. Mol Biol Cell. 2001;12(12):4103–13.
41. Cuyàs E, Coromnas-Faja, Joven J, et al. Cell cycle regulation by the nutrient-sensing mammalian target of rapamycin (mTOR) pathway. In: Noguchi E, Gadaleta MC, editors. Cell cycle control: mechanisms and protocols. Springer; New York; 2014. pp. 113–144.
42. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129(7):1261–74.
43. Heras-Sandoval D, Perez-Rojas JM, Hernandez-Damian J, et al. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal. 2014;26(12):2694–701.
44. Dudek H, Datta SR, Franke TJ, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 1997;275(5300):661–5.
45. Brunet A, Datta SR, Greenberg ME. Transcription-dependent and -independent control of neuronal survival by the PI3K–Akt signaling pathway. Curr Opin Neurobiol. 2001;11(3):297–305.
46. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT—a major therapeutic target. Biochimica et Biophysica Acta. 2004;1697(1–2):3–16.
47. Li Y, Inoki K, Yeung R, Guan KL. Regulation of TSC2 by 14-3-3 binding. J Biol Chem. 2002;277(47):44593–6.
48. Long X, Lin Y, Ortiz-Vega S, et al. Rheb binds and regulates the mTOR kinase. Curr Biol. 2005;15(8):702–13.
49. Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene. 2006;25(48):6347–60.
50. Nazio F, Strappazzon F, Antonioli M, et al. mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. Nat Cell Biol. 2013;15(4):406–16.
51. Sato T, Nakashima A, Guo L, et al. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene. 2010;29(18):2746–52.
52. Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004;166(2):213–23.
53. Chen J, Long F. mTORC1 signaling controls mammalian skeletal growth through stimulation of protein synthesis. Development. 2014;141(14):2848–54.
54. Guan Y, Yang X, Yang W, et al. Mechanical activation of mammalian target of rapamycin pathway is required for cartilage development. FASEB J. 2014;28(10):4470–81.
55. Rokutanda S, et al. Akt regulates skeletal development through GSK3, mTOR, and FoxOs. Develop Biol. 2009;328:78–93. doi:10.1016/j.ydbio.2009.01.009.
56. Phornphutkul C, Wu KY, Augeung V, et al. mTOR signaling contributes to chondrocyte differentiation. Dev Dyn. 2008;237(3):702–12.
57. Alvarez-Garcia O, Garcia-Lopez E, Loredo V, et al. Rapamycin induces growth retardation by disrupting angiogenesis in the growth plate. Kidney Int. 2010;78(6):561–8.
58. Phornphutkul C, Lee M, Voigt C, et al. The effect of rapamycin on bone growth in rabbits. J Orthop Res. 2009;27(9):1157–61.
59. Sanchez CP, He YZ. Bone growth during rapamycin therapy in young rats. BMC Pediatr. 2009;9:3.
60. Oh CD, Kim SJ, Ju JW, et al. Immunosuppressant rapamycin inhibits protein kinase C alpha and p38 mitogen-activated protein kinase leading to the inhibition of chondrogenesis. Eur J Pharmacol. 2001;427(3):175–85.
61. Chen J, Holguin N, Shi Y, et al. mTORC2 signaling promotes skeletal growth and bone formation in mice. J Bone Miner Res. Epub 4 Sep 2014.
62. Tchetina EV. The importance of the mTOR regulatory network in chondrocyte biology and osteoarthritis. EMJ Rheumatol. 2014;1:84–95.
63. Tchetina EV, Poole AR, Zaitseva EM, et al. Differences in mammalian target of rapamycin gene expression in the peripheral blood and articular cartilages of osteoarthritic patients and disease activity. Arthritis. 2013;2013:461486.
64. Zhang Y, Vasheghani F, Li YH, et al. Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-204599.
65. Sasaki H, Takayama K, Matsushita T, et al. Autophagy modulates osteoarthritis-related gene expression in human chondrocytes. Arthritis Rheum. 2012;64(6):1920–8.
66. Carames B, Taniguchi N, Seino D, et al. Mechanical injury suppresses autophagy regulators and pharmacologic activation of autophagy results in chondroprotection. Arthritis Rheum. 2012;64(4):1182–92.
67. Wu C, Zheng J, Yao X, et al. Defective autophagy in chondrocytes with Kashin-Beck disease but higher than osteoarthritis. Osteoarthritis Cartilage. 2014;22(11):1936–46.
68. Chang J, Wang W, Zhang H, et al. The dual role of autophagy in chondrocyte responses in the pathogenesis of articular cartilage degeneration in osteoarthritis. Int J Mol Med. 2013;32(6):1311–8.
69. Matsuzaki T, Matsushita T, Tabata Y, et al. Intra-articular administration of gelatin hydrogels incorporating rapamycin-micelles reduces the development of experimental osteoarthritis in a murine model. Biomaterials. 2014;35(37):9904–11.
70. Takayama K, Kawakami Y, Kobayashi M, et al. Local intra-articular injection of rapamycin delays articular cartilage degeneration in a murine model of osteoarthritis. Arthritis Res Ther. 2014;16(6):482.
71. Carames B, Hasegawa A, Taniguchi N, et al. Autophagy activation by rapamycin reduces severity of experimental osteoarthritis. Ann Rheum Dis. 2012;71(4):575–81.
72. Kapoor M, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7(1):33–42.
73. Liu N, et al. Autophagy in human articular chondrocytes is cytoprotective following glucocorticoid stimulation. Mol Med Rep. 2014;9(6):2166–72.
74. Huang MJ, et al. Enhancement of the synthesis of n-3 PUFAs in fat-1 transgenic mice inhibits mTORC1 signalling and delays surgically induced osteoarthritis in comparison with wild-type mice. Ann Rheum Dis. 2014;73(9):1719–27.
75. Weng T, et al. Loss of Vhl in cartilage accelerated the progression of age-associated and surgically induced murine osteoarthritis. Osteoarthritis Cartilage. 2014;22(8):1197–205.
76. Zeng G, et al. Disruption of phosphoinositide-specific phospholipases Cgamma1 contributes to extracellular matrix synthesis of human osteoarthritis chondrocytes. Int J Mol Sci. 2014;15(8):13236–46.
77. Carames B, et al. Glucosamine activates autophagy in vitro and in vivo. Arthritis Rheum. 2013;65(7):1843–52.
78. Hosokawa N, et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell. 2009;20(7):1981–91.
79. Lee JW, et al. The association of AMPK with ULK1 regulates autophagy. PLoS One. 2010;5(11):e15394.
80. Dunlop EA, et al. ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate binding. Autophagy. 2011;7(7):737–47.
81. Blagosklonny MV. Hypoxia, MTOR and autophagy: converging on senescence or quiescence. Autophagy. 2013;9(2):260–2.
82. Demidenko ZN, Zubova SG, Bukreeva EI, et al. Rapamycin decelerates cellular senescence. Cell Cycle. 2009;8(12):1888–95.
83. Narita M, et al. Spatial coupling of mTOR and autophagy augments secretory phenotypes. Science. 2011;332(6032):966–70.
84. Young AR, Narita M, Narita M. Spatio-temporal association between mTOR and autophagy during cellular senescence. Autophagy. 2011;7(11):1387–8.
85. Zoncu R, Sabatini DM. Cell biology. The TASCC of secretion. Science. 2011;332(6032):923–5.
86. Powers RW 3rd, et al. Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev. 2006;20(2):174–84.
87. Vellai T, et al. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature. 2003;426(6967):620.
88. Kapahi P, et al. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol. 2004;14(10):885–90.
89. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392–5.
90. Seto B. Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer. Clin Transl Med. 2012;1(1):29.
91. Canaud G, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014;371(4):303–12.
92. Fernandez D, et al. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2983–8.
93. Fried L, et al. Efficacy of rapamycin in scleroderma: a case study. Lymphat Res Biol. 2008;6(3–4):217–9.
94. Nadiminti U, Arbiser JL. Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J Am Acad Dermatol. 2005;52(2, Supplement):S17–9.
95. Yoshizaki A, et al. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum. 2010;62(8):2476–87.
96. Chen J, Crawford R, Xiao Y. Vertical inhibition of the PI3K/Akt/mTOR pathway for the treatment of osteoarthritis. J Cell Biochem. 2013;114(2):245–9.
97. US National Institutes of Health. A pilot study evaluating the use of mTor inhibitor sirolimus in children and young adults with desmoid-type fibromatosis. 2010. http://clinicaltrials.gov/ct2/show/NCT01265030?term=mtor&rank=8. Accessed 20 Dec 2014.
98. US National Institutes of Health. Gemcitabine plus rapamycin versus gemcitabine to treat advanced soft tissue sarcoma. 2010. http://clinicaltrials.gov/ct2/show/NCT01684449?term=mTOR&rank=61. Accessed 20 Dec 2014.
99. US National Institutes of Health. Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease (RAP). 2014. http://clinicaltrials.gov/ct2/show/NCT02055079?term=mTOR&rank=64. Accessed 20 Dec 2014.
100. US National Institutes of Health. Controlled level EVERolimus in acute coronary syndromes (CLEVER-ACS). 2012. https://clinicaltrials.gov/ct2/show/NCT01529554. Accessed 20 Dec 2014.
101. US National Institutes of Health. Prospective study of rapamycin for the treatment of SLE (Rapamune). 2008. https://clinicaltrials.gov/ct2/show/NCT00779194. Accessed 20 Dec 2014.
102. US National Institutes of Health. A phase II study of EVEROLIMUS in patients with primary or relapsed chondrosarcomas (CHONRAD). 2013. http://clinicaltrials.gov/ct2/show/NCT02008019?term=rapamycin&rank=68. Accessed 20 Dec 2014
103. US National Institutes of Health. Everolimus and lenalidomide in treating patients with relapsed or refractory non-Hodgkin or Hodgkin lymphoma. 2010. https://clinicaltrials.gov/ct2/show/NCT01075321. Accessed 20 Dec 2014.
104. US National Institutes of Health. Daily everolimus in combination with trastuzumab and vinorelbine in HER2/Neu positive women with locally advanced or metastatic breast cancer (BOLERO-3). 2009. http://clinicaltrials.gov/ct2/show/NCT01007942?term=NCT01007942&rank=1. Accessed 20 Dec 2014.
105. US National Institutes of Health. Neoadjuvant rapamycin in patients undergoing radical cystectomy. 2013. https://clinicaltrials.gov/ct2/show/NCT01827618. Accessed 20 Dec 2014.
106. Hudes G, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.
107. Rangwala R, et al. Combined MTOR and Autophagy Inhibition: PHASE I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy. 2014;10(8):9–20.
108. Yee AJ, et al. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014;166(3):401–9.
109. Bagatell R, et al. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children’s Oncology Group Study. Pediatr Blood Cancer. 2014;61(5):833–9.